Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic derivative of tyrosine, featuring a hydroxy group and an amino substitution at the 5-position with a (1-{(naphthyloxy)methyl}-3 oxopropenyl) moiety. It is classified as an experimental small molecule and has not been approved for clinical use. The compound has been studied primarily in biochemical contexts, such as ligand binding studies or enzyme inhibition assays. Its mechanism of action and pharmacological targets are not well characterized in the literature; however, it has been referenced in relation to phenylethylamine oxidase from Arthrobacter globiformis as an experimental ligand[5]. No clinical indications or therapeutic uses are reported[1][2][3][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-Hydroxy-5-({1-[(2-Naphthyloxy)Methyl]-3-Oxoprop-1-Enyl}Amino)Tyrosine.